2,5-Dihydroxybenzenesulfonic acid
metaboliteDifferential metabolite accumulating in post-MI cardiac dysfunction and ischemic injury.
Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencelow
RationalePost-MI metabolite dysregulation associated with cardiac function decline.
Also acts inSystemic / off-pathway
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Serum untargeted metabolomics analysis of mice after myocardial infarction affected by qiliqiangxin capsule.Journal of pharmaceutical and biomedical analysis · 2024 · PMID 39405786 · doi